$ARWR News

People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides

Arrowhead Pharma’s REDEMPLO Authorized In EU; Now Prescribable And Reimbursable In Germany For Familial Chylomicronaemia Syndrome

‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit

HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120

ARWR: Acquires PRV for sNDA Submission for Plozasiran in sHTG

Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ...

Arrowhead Pharmaceuticals Q3 Earnings Call Highlights

Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2026 Earnings Call Transcript

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher

Arrowhead Pharma Q3 EPS $(1.36) Misses $(1.32) Estimate, Sales $75.253M Beat $54.294M Estimate

Arrowhead Pharmaceuticals Enters Agreement With Undisclosed Third Party To Acquire An FDA Rare Pediatric Disease Priority Review Voucher For Its Upcoming SNDA Submission For Plozasiran, Anticipated Before The End Of 2026

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

B. Riley Securities Maintains Buy on Arrowhead Pharma, Raises Price Target to $123

The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Dual Phase 3 RNAi Cardiometabolic Milestones

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals Completes Patient Enrollment In Its Global Phase 3 YOSEMITE Clinical Study Of Zodasiran To Treat Homozygous Familial Hypercholesterolemia

HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $115

Morgan Stanley Maintains Overweight on Arrowhead Pharma, Raises Price Target to $120

Piper Sandler Reiterates Overweight on Arrowhead Pharma, Raises Price Target to $126